Adipotide, also known as FTPP, is an experimental weight loss treatment that kills fat cells by targeting the blood supply of those cells.

5-amino-1MQ is a small molecule that blocks the activity of the enzyme called nicotinamide N-methyltransferase (NNMT). By blocking NNMT, 5-amino-1MQ stimulates an increase in NAD+, a cofactor that is central to cellular metabolism, thereby increasing metabolic rate and activating a gene called sirtuin-1 (SIRT1). SIRT1 is also known as the "longevity gene" because of its role in reducing the risk of diabetes, obesity, metabolic syndrome, atherosclerosis and other forms of cardiovascular disease, kidney disease, liver disease, neurodegeneration, and cancer.

  Orforglipron (LY3502970, OWL833) is a highly orally bioavailable small-molecule partial activator of the GLP-1 receptor. Through G-protein–coupled pathways, it replicates incretin effects while maintaining receptor sensitivity. Studies show it promotes improved body composition, metabolic balance, better glucose control, and enhanced beta-cell protection. It also helps balance cholesterol and inflammatory markers, contributing to cardiovascular and metabolic wellness. These findings suggest Orforglipron may play an important role in supporting overall metabolic efficiency and cellular resilience.

Semaglutide is a widely researched peptide-based compound recognized for its significant role in metabolic regulation and appetite control. It belongs to the class of GLP-1 receptor agonists, which are designed to mimic naturally occurring hormones involved in glucose metabolism and satiety signaling.